[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.112.177. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1985

Topical Prostaglandin E2 in the Treatment of Acute Upper Gastrointestinal Tract HemorrhageA Prospective, Randomized, Double-blind Study

Author Affiliations

From the Department of Surgery, Audie Murphy Veterans Administration Hospital, San Antonio, Tex, and the Department of Surgery, University of Texas Health Science Center at San Antonio.

Arch Surg. 1985;120(5):600-604. doi:10.1001/archsurg.1985.01390290078013
Abstract

• We performed a prospective, randomized, double-blind study to assess the efficacy of topical prostaglandin E2 (PGE2) in altering the course of patients with severe upper gastrointestinal tract hemorrhage. Forty-four patients with life-threatening, endoscopically proven hemorrhage were randomly allocated to receive either PGE2 or placebo for seven days. Severity of mucosal injury, determined by endoscopy, was scored both before and after completion of treatment. There were no significant differences between groups in either transfusion requirements or successful outcomes. However, the PGE2 group had significantly improved endoscopic injury scores while the placebo group did not. Therefore, topical PGE2 does not control acute hemorrhage from established upper gastrointestinal tract lesions, but it does result in an accelerated healing of established lesions.

(Arch Surg 1985;120:600-604)

×